Searchable abstracts of presentations at key conferences in endocrinology

ea0022p565 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Daily temozolomide therapy in Nelson's syndrome

Ortiga Ruth Sanchez , Sanchez Victor L Gonzalez , Perez Oscar Moreno , Meana Andres , Alfonso Antonio A Pico

Temozolomide, an alkylating agent used in malignant gliomas, has been recently used too in the treatment of aggressive pituitary tumors. To date, two cases of Nelson’s syndrome has successfully treated with 5 days of 28-day cycle, but the follow-up has been shorter than 12 months. We reported the third patient with Nelson’s syndrome treated with temozolomide, who after an initial goal response to three 300 mg 5 days of 28-day cycles shown a clinical and biochemical (...

ea0037ep669 | Pituitary: basic and neuroendocrinology | ECE2015

MiR-7 has a role in behaviour of somatotroph adenomas

Sanchez-Ortiga Ruth , Sanchez-Tejada Laura , Lamas Cristina , Camara Rosa , Abarca Javier , Monjas Irene , Riesgo Pedro , Fajardo Carmen , Pico Antonio

Purpose: IGF receptor 1 (IGF1R) and epidermal growth factor receptor (EGFR) are receptors tyrosine-kinase (RTK) whose altered signaling are critical factors in development of many types of tumours. These RTK are some of the main targets of the microRNA miR-7. This important tumor supressor miRNA has the ability to inhibit the motility, invasiveness and anchorage-independent growth, suggesting a strong therapeutic potential in many types of cancer. Pituitary adenomas (PA) are a...